Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Standard Biotools (LAB) EBT (2016 - 2025)

Standard Biotools (LAB) has disclosed EBT for 16 consecutive years, with -$32.9 million as the latest value for Q3 2025.

  • On a quarterly basis, EBT fell 51.13% to -$32.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was -$143.3 million, a 118.56% decrease, with the full-year FY2024 number at -$138.3 million, down 240.78% from a year prior.
  • EBT was -$32.9 million for Q3 2025 at Standard Biotools, down from -$18.3 million in the prior quarter.
  • In the past five years, EBT ranged from a high of $153.3 million in Q4 2022 to a low of -$76.9 million in Q1 2022.
  • A 5-year average of -$18.2 million and a median of -$20.9 million in 2023 define the central range for EBT.
  • Peak YoY movement for EBT: surged 1596.3% in 2022, then crashed 531.88% in 2024.
  • Standard Biotools' EBT stood at -$10.2 million in 2021, then soared by 1596.3% to $153.3 million in 2022, then crashed by 91.07% to $13.7 million in 2023, then plummeted by 531.88% to -$59.1 million in 2024, then skyrocketed by 44.23% to -$32.9 million in 2025.
  • Per Business Quant, the three most recent readings for LAB's EBT are -$32.9 million (Q3 2025), -$18.3 million (Q2 2025), and -$33.0 million (Q1 2025).